1085 results about "P phosphate" patented technology

Dinucleotide cap analogs are disclosed, modified at different phosphate positions with a boranophosphate group or a phosphoroselenoate group. The analogs are useful as reagents in the preparation of capped mRNAs and have increased stability both in vitro and in vivo. They may be used as inhibitors of cap-dependent translation. Optionally, the boranophosphate or phosphoroselenoate group has a 2′-O or 3′-O-alkyl group, preferably a methyl group, producing analogs called BH3-ARCAs or Se-ARCAs. ARCAs may be modified with α-, β-, or γ-boranophosphate or phosphoroselenoate groups.

A method of characterizing an analyte sample is provided that includes the steps of: (a) anchoring the analyte to a nucleic acid template of known sequence; (b) conducting a DNA polymerase reaction that includes the reaction of a template, a non-hydrolyzable primer, at least one terminal phosphate-labeled nucleotide, DNA polymerase, and an enzyme having 3'->5' exonuclease activity which reaction results in the production of labeled polyphosphate; (c) permitting the labeled polyphosphate to react with a phosphatase to produce a detectable species characteristic of the sample; (d) detecting the detectable species. The method may include the step of characterizing the nucleic acid sample based on the detection. Also provided are methods of analyzing multiple analytes in a sample, and kits for characterizing analyte samples.

A class of 2′-fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer. The compounds have the general formulae: wherein[0001]Base is a purine or pyrimidine base;[0002]R1 is OH, H, OR3, N3, CN, halogen, including F, or CF3, lower alkyl, amino, loweralkylamino, di(lower)alkylamino, or alkoxy, and base refers to a purine or pyrimidine base;[0003]R2 is H, phosphate, including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug; acyl, or other pharmaceutically acceptable leaving group which when administered in vivo, is capable of providing a compound wherein R2 is H or phosphate; sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl, benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given above, a lipid, an amino acid, peptide, or cholesterol; and[0004]R3 is acyl, alkyl, phosphate, or other pharmaceutically acceptable leaving group which when administered in vivo, is capable of being cleaved to the parent compound, or a pharmaceutically acceptable salt thereof.

Methods of enhancing fluid flow through a vascular site occupied by a vascular occlusion, as well as systems and kits for use in practicing the same, are provided. In practicing the subject methods, the vascular site is flushed simultaneously with a first dissolution fluid (e.g., an organic matter dissolution fluid and / or an inorganic matter dissolution fluid), and a second dissolution fluid attenuating fluid, where flushing is carried out in a manner such that only a surface of the vascular occlusion is contacted with the non-attenuated dissolution fluid. Examples of dissolution fluid / dissolution fluid attenuating fluid pairs include: (1) oxidizing agent fluid and fluid comprising oxidizable neutralizing agent; (2) surfactant fluid and phosphate buffered saline; (3) acidic solution and phosphate buffered saline; etc. Flushing is carried out in this manner for a period of time sufficient for fluid flow through the vascular site to be enhanced, e.g. increased or established. The subject methods, systems and kits for practicing the same find use in the treatment of a variety of different vascular diseases characterized by the presence of vascular occlusions, including both partial and total occlusions.

Methods of enhancing fluid flow through a vascular site occupied by a vascular occlusion, as well as systems and kits for use in practicing the same, are provided. In practicing the subject methods, the vascular site is flushed simultaneously with a first dissolution fluid (e.g., an organic matter dissolution fluid and / or an inorganic matter dissolution fluid), and a second dissolution fluid attenuating fluid, where flushing is carried out in a manner such that only a surface of the vascular occlusion is contacted with the non-attenuated dissolution fluid. Examples of dissolution fluid / dissolution fluid attenuating fluid pairs include: (1) oxidizing agent fluid and fluid comprising oxidizable neutralizing agent; (2) surfactant fluid and phosphate buffered saline; (3) acidic solution and phosphate buffered saline; etc. Flushing is carried out in this manner for a period of time sufficient for fluid flow through the vascular site to be enhanced, e.g. increased or established. The subject methods, systems and kits for practicing the same find use in the treatment of a variety of different vascular diseases characterized by the presence of vascular occlusions, including both partial and total occlusions.

A lithium ion electrochemical cell having high charge / discharge capacity, long cycle life and exhibiting a reduced first cycle irreversible capacity, is described. The stated benefits are realized by the addition of at least one phosphate additive to an electrolyte comprising an alkali metal salt dissolved in a solvent mixture that includes ethylene carbonate, dimethyl carbonate, ethylmethyl carbonate and diethyl carbonate. The preferred additive is an alkyl phosphate compound.

Phosphorus-based coatings having a plurality of phosphate moieties, a plurality of phosphonate moieties, or both, covalently bonded to an oxide surface of an implantable substrate exhibiting one or more of the following characteristics: (a) the surface phosphorus-containing group density of the coated regions of the substrate is at least about 0.1 nmol / cm2; (b) the phosphorus-based coating has a thickness of less than about 10 nm; or (c) the surface phosphorus-containing group density of the coated regions of the substrate is equal to or greater than the surface hydroxyl group density of the oxide surface of the substrate. Implantable devices embodying the coated substrates are also disclosed.

Compositions and methods for treating osteoporosis using the compositions are disclosed where the compositions have reduced GI toxicity and improved bio-availability and include a bisphosphonate and zwitterionic phospholipid.

The invention is directed to formulations of GLP-2 peptides and analogs thereof exhibiting superior stability following storage and / or exposure to elevated temperatures. The GLP-2 compositions comprise a GLP-2 peptide or an analog thereof, a phosphate buffer, L-histidine, and mannitol.

The present invention is directed to compositions, products and methods useful for bone and tooth mineralization. The compositions comprise polymer microcapsules containing aqueous salt solutions. The shells of the microcapsules can be semi-permeable or impermeable. Solutions of calcium, fluoride and phosphate salts are particularly useful in the compositions of the invention. The microcapsules are preferably prepared by surfactant free inverse emulsion interfacial polymerization. Bone products include cements, scaffolds and bioactive glass. Dental products include pastes, gels, rinses and many other dental materials.

A partially soluble lanthanide compound and methods for use in removing phosphate from water. Preferably the compound is used in removing phosphate from water in swimming pools, spas, and similar structures. Alternatively, a combination of compounds having varying solubilities may be used to remove phosphate from water. Several water treatment techniques are disclosed, as well as a variety of different methods for delivery of the active ingredients. These delivery methods include use of a slurry of the active reagent in solution as well as a tablet, powder, or granulated structure. Additionally, the water treatment techniques may incorporate the use of a combination including both enzymatic compositions and compounds for phosphate removal.

The invention relates to a phosphate material having a mesoporous structure for lithium secondary batteries and a preparation method thereof. The material having a mesoporous structure is secondary particles which have a mesoporous spherical or spheroid shape and are formed by the agglomeration of primary particles; the chemical composition of the material having the mesoporous structure is represented by the formula of LixAaMmBbPOzNn; the average particle diameter of the primary particles is 10nm to 1mum, the average particle diameter of the secondary particles is 100nm to 50mum, the average pore diameter of mesopores is 2 to 500nm; and the material having the mesoporous structure also comprises a layer of 2 to 100nm thick carbon coated outside the secondary particles and on the inner walls of the mesopores, wherein the content of the carbon accounts for 1 to 20 weight percent of the total weight of a substrate. The material is prepared by the steps of: firstly preparing pure-phase phosphate LiMPO4 or doped LiMPO4 sol; secondly, forming dry gel through heat treatment; and finally, forming the agglomerate secondary particles through sintering at high temperature. The phosphate material having the mesoporous structure can be directly used in secondary lithium batteries as an anode active material and can also be used by being mixed with the prior anode material as an additive. The material having the mesoporous structure can improve the rate performance and energy density of the prior anode material and batteries. The secondary lithium batteries containing the phosphate material having the mesoporous structure has high power density and high safety.

Methods of enhancing fluid flow through a vascular site occupied by a vascular occlusion, as well as systems and kits for use in practicing the same, are provided. In practicing the subject methods, the vascular site is flushed simultaneously with a first dissolution fluid (e.g., an organic matter dissolution fluid and / or an inorganic matter dissolution fluid), and a second dissolution fluid attenuating fluid, where flushing is carried out in a manner such that only a surface of the vascular occlusion is contacted with the non-attenuated dissolution fluid. Examples of dissolution fluid / dissolution fluid attenuating fluid pairs include: (1) oxidizing agent fluid and fluid comprising oxidizable neutralizing agent; (2) surfactant fluid and phosphate buffered saline; (3) acidic solution and phosphate buffered saline; etc. Flushing is carried out in this manner for a period of time sufficient for fluid flow through the vascular site to be enhanced, e.g. increased or established. The subject methods, systems and kits for practicing the same find use in the treatment of a variety of different vascular diseases characterized by the presence of vascular occlusions, including both partial and total occlusions.

There is disclosed a composition and a method for the efficient non-viral delivery of nucleic acids to cells using chitosan. In order to achieve high efficiency of transfection, the composition contains a nucleic acid and a chitosan that has the following physico-chemical properties: a combination of a number-average molecular weight between 8 kDa and 185 kDa and a degree of deacetylation between 72% and 92%. The chitosan molecule can also present additional physiochemical properties such as a block distribution of acetyl groups obtained by a heterogeneous treatment of chitin, and / or a polydispersity index between 1.4 and 7.0. By correctly controlling these parameters, efficient delivery systems may be produced that are effective when optimized for different conditions such as the pH of transfection media and amine-to-phosphate ratio.

A flame retardant composition includes, as essential components having two specified types of phosphate compounds; silicon dioxide or metal oxides; and at least one member selected from among higher aliphatic carboxylic acids, metal salts of higher aliphatic carboxylic acid, higher fatty acid amide compounds, and esters between mono- or polyhydric alcohols and higher aliphatic carboxylic acids. This flame retarder composition is free from secondary agglomeration, and does not need incorporation of a halogenated flame retarder that when blended in a synthetic resin, releases harmful gas at combustion. The flame retardant composition enables imparting flame retardant properties to synthetic resins with the use of a small amount of flame retarder.

An improved method for the manufacture of gelling carrageenens from seaweed, wherein mono-component seaweed is subjected to a heterogeneous reaction step, one or more washing step (s), and further workup provides for substantial savings in alkali costs as non-expensive alkalis, such as NaOH, Na2CO3,Na-phosphates, K2CO3, K-phosphates, ammonia may be used in the heterogeneous reaction step.

A method of characterizing an analyte sample is provided that includes the steps of: (a) anchoring the analyte to a nucleic acid template of known sequence; (b) conducting a DNA polymerase reaction that includes the reaction of a template, a non-hydrolyzable primer, at least one terminal phosphate-labeled nucleotide, DNA polymerase, and an enzyme having 3′→5′ exonuclease activity which reaction results in the production of labeled polyphosphate; (c) permitting the labeled polyphosphate to react with a phosphatase to produce a detectable species characteristic of the sample; (d) detecting the detectable species. The method may include the step of characterizing the nucleic acid sample based on the detection. Also provided are methods of analyzing multiple analytes in a sample, and kits for characterizing analyte samples.

This invention relates to waterborne coating compositions having improved compatability with metal pigments, i.e., improved shelf life and reduced gassing and gellation. The compositions comprise at least one aqueous dispersion of (1) at least one emulsion copolymer polymerized from (a) at least one ethylenically unsaturated anionic monomer and (b) at least one other olefinically unsaturated monomer, said copolymer being made using at least one phosphate surfactant having at least one phosphorus acid group or salt thereof, said copolymer being crosslinked, and (2) at least one non-water soluble metal pigment. The compositions are useful in paints and other coatings.

The present invention discloses an inorganic bone adhesive and its use in human hard tissue repairs. The inorganic bone adhesive comprises basic compound, phosphate, calcium phosphate bone cement and retarder with the characteristics of rapid hydration rate and high early strength. Inorganic Bone adhesive can be widely used in the artificial joints fixation, screw fixation as well as comminuted fracture fixation. It is a kind of safe and effective adhesive material and beneficial for the fast postoperative recovery. The final hydration reaction products contains the composition of magnesium phosphate, bio-mineral containing ammonium and apatite-like materials, which has excellent biocompatibility and can be gradually absorbed by surrounding tissues after being implanted in vivo, which benefits the in-growth of the new bone.

The present invention relates to phosphate-binding compounds that find use in binding, detecting and isolating phosphorylated target molecules including the subsequent identification of target molecules that interact with phosphorylated target molecules or molecules capable of being phosphorylated. A binding solution is provide that comprises a phosphate-binding compound, an acid and a metal ion wherein the metal ion simultaneously interacts with an exposed phosphate group on a target molecule and the metal chelating moiety of the phosphate-binding compound forming a bridge between the phosphate-binding compound and a phosphorylated target molecule resulting in a ternary complex. The binding solution of the present invention finds use in binding and detecting immobilized and solubilized phosphorylated target molecules, isolation of phosphorylated target molecules from a complex mixture and aiding in proteomic analysis wherein kinase and phosphatase substrates and enzymes can be identified.

The present invention relates to compositions and methods employing 5′-phosphate-dependent nucleic acid exonucleases. In particular, the present invention provides kits and methods employing 5′-phosphate-dependent nucleic acid exonucleases for selective enrichment, isolation and amplification of a particular set of desired nucleic acid molecules from samples that also contain undesired nucleic acid molecules for a variety of uses. In preferred embodiments, the desired nucleic acid molecules comprise prokaryotic and / or eukaryotic mRNA.

Nucleotide triphosphate probes containing a molecular and / or atomic tag on a a γ and / or β phosphate group and / or a base moiety having a detectable property are disclosed, and kits and method for using the tagged nucleotides in sequencing reactions and various assay. Also, phosphate and polyphosphate molecular fidelity altering agents are disclosed.

The invention relates to a chitosan modified alginate hydrogel three-dimensional porous bracket with specific in-vitro degradability and a preparation method thereof. The method comprises the following steps: dissolving sodium alga acid serving as a raw material in phosphate buffer solution; performing amidation reaction of a carboxyl group in the sodium alga acid and an amino group in a cross-linking agent cystamine or dimethyl cystinate under the activation of water-soluble carbodiimide to form a chemically crosslinked hydrogel; performing freeze drying on the hydrogel to obtain a porous bracket material of the hydrogel; and performing surface modification on the porous bracket by using chitosan. In solution of a reducing agent such as cysteine with an appropriate concentration, a disulfide bond in a hydrogel cross-bridge is degraded through a disulfide bond-sulfydryl conversion reaction, so the porous bracket is decomposed and dissolved and disappears. Therefore, the porous bracket can be used as an in-vitro cell culture template material. The hydrogel porous bracket researched by the invention has the characteristics of simple preparation, rich raw material source, low cost and availability. Various physiochemical performances, mechanical strength, degradation rate and surface properties of the bracket material are controllable within a large range.

Stabilized preparations which contain a beta-lactam antibiotic having an esterified carboxyl group attached directly to the mother nucleus, an oil and a phosphate.

According to the invention, there is provided a phosphate derivative of a phenolic hydroxy compound comprising the reaction product of the following steps: (d) reacting the phenolic hydroxy compound with an alkyl α:ω dialdehyde or a sugar-like polyhydroxy dialdehyde to form a hemiacetal; (e) reducing the terminal aldehyde group on the product from step (a) to a hydroxyl group; and (f) phosphorylating the hydroxyl group formed in step (b) to produce a phosphate derivative of the phenolic hydroxy compound.

The present invention relates to preparation method for an array substrate for the use in a liquid crystal display device, using an etchant composition comprising: a) 5-25 wt% of hydrogen peroxide (H2O2); b) 0.1-5 wt% of an organic acid; c) 0.1-5 wt% of a phosphate compound; d) 0.1-5 wt% of a water-soluble cyclic amine compound; e) 0.1-5 wt% of a water-soluble compound having a nitrogen atom and a carboxyl group in a molecule; f) 0.01-1.0 wt% of a fluorine-containing compound; g) 0.001-5 wt% of a polyhydric alcohol-based surfactant; and h) the balance of water based on the total weight of the composition.

Methods for forming proppant pillars in a formation during formation fracturing include include periods of pumping a first fracturing fluid including a proppant and an aggregating composition including a reaction product of a phosphate compound or a plurality of phosphate and an amine, periods of pumping a second fracturing fluid excluding a proppant and an aggregating composition including a reaction product of a phosphate compound and periods of pumping a third fracturing fluid including an aggregating composition including a reaction product of a phosphate compound, where the pumping of the three fracturing fluids may be in any order and may involve continuous pumping, pulse pumping, or non-continuous pumping.

The aqueous thermosetting neutralized chitosan composition, forming a phosphate-free transparent hydrogel at a temperature higher than 5° C., comprises 0.1 to 5.0 w / w %, based on the total composition, of a reacetylated chitosan having a molecular weight of not smaller than 100 kDa and a deacetylation degree of 40 to 70%, neutralized with an hydroxylated base, and 1 to 30 w / w %, based on the total composition, of a complexing agent selected from polyoses and polyols derived from polyoses. Said composition is useful for the preparation of an injectable formulation.